Advanced strain elastography is a reliable approach for prostate cancer detection in patients with elevated PSA levels
-
Published:2024-02-05
Issue:1
Volume:14
Page:
-
ISSN:2045-2322
-
Container-title:Scientific Reports
-
language:en
-
Short-container-title:Sci Rep
Author:
Almalki Yassir Edrees,Mansour Mohamed Gamal El-Din,Ali Susan Adil,Basha Mohammad Abd Alkhalik,Abdelkawi Moustafa Mahmoud,Alduraibi Sharifa Khalid,Almushayti Ziyad A.,Aldhilan Asim S.,Aboualkheir Mervat,Amin Darine,Metkees Mohamed,Basha Ahmed M. A.,Ebaid Noha Yahia
Abstract
AbstractThis study aimed to examine the validity and reproducibility of strain elastography (SE) for detecting prostate cancer (PCa) in patients with elevated prostate-specific antigen (PSA) levels. The study included 107 patients with elevated PSA levels. All eligible patients underwent transrectal ultrasound (TRUS) with real-time elastography (RTE) to detect suspicious lesions. Two readers independently evaluated the lesions and assigned a strain ratio and elastography score to each lesion. Histopathology was used as a reference standard to estimate the validity of RTE in predicting malignant lesions. An intraclass correlation (ICC) was performed to detect reliability of the strain ratios and elastography scores. TRUS-guided biopsy detected malignancies in 64 (59.8%) patients. TRUS with RTE revealed 122 lesions. The strain ratio index (SRI) cut-off values to diagnose malignancy were 4.05 and 4.35, with sensitivity, specificity, and accuracy of 94.7%, 91.3%, and 93.4%, respectively. An elastography score > 3 was the best cut-off value for detecting malignancy. According to readers, the sensitivity, specificity, and accuracy were 91.3–94.7%, 89.5–93.4%, and 91.3–90.9%, respectively. Excellent inter-reader agreement was recorded for SRI and elastography scores, with ICC of 0.937 and 0.800, respectively. SE proves to be an efficient tool for detecting PCa with high accuracy in patients with elevated PSA levels.
Funder
Deanship of Scientific Research, Najran University, Kingdom of Saudi Arabia
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. CA Cancer J. Clin. 68(1), 7–30 (2018). 2. Gómez Veiga, F., Ponce Reixa, J., Barbagelata López, A., Fernández Rosado, E. & Gonzaĺez, M. M. Current role of PSA and other markers in the diagnosis of prostate cancer. Archivos Espanoles de Urologia 59(10), 1069–1082 (2006). 3. Heidenreich, A. et al. EAU guidelines on prostate cancer. Part I: Screening, diagnosis, and treatment of clinically localised disease. Actas Urologicas Espanolas 35(9), 501–514 (2011). 4. Borza, T., Konijeti, R. & Kibel, A. S. Early detection, PSA screening, and management of over-diagnosis. Hematol. Oncol. Clin. N. Am. 27(6), 1091–1110 (2013). 5. Boesen, L., Norgaard, N., Logager, V., Balslev, I. & Thomsen, H. S. Where do transrectal ultrasound- and magnetic resonance imaging-guided biopsies miss significant prostate cancer?. Urology 110, 154–160 (2017).
|
|